



A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients

Xiangkun Wu^{1,2#^}, Daojun Lv^{1,2#}, Md Eftekhar³, Aisha Khan⁴, Chao Cai^{1,2}, Zhijian Zhao^{1,2}, Di Gu^{1,2}, Yongda Liu^{1,2^}

¹Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; ²Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, China; ³Department of Family Medicine, CanAm International Medical Center, Shenzhen, China; ⁴Department of Family Medicine, Yunshan Medical Hospital, Shenzhen, China

Contributions: (I) Conception and design: YD Liu, D Gu; (II) Administrative support: YD Liu, D Gu; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Cai, Z Zhao, M Eftekhar, A Khan; (V) Data analysis and interpretation: X Wu, D Lv; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Prof. Yongda Liu; Di Gu, PhD. Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Kangda Road 1#, Haizhu District, Guangzhou 510230, China. Email: 13719007083@163.com; di.gu@nhs.net.

Background: Biochemical recurrence (BCR) is considered a decisive risk factor for clinical recurrence and the metastasis of prostate cancer (PCa). Therefore, we developed and validated a signature which could be used to accurately predict BCR risk and aid in the selection of PCa treatments.

Methods: A comprehensive genome-wide analysis of data concerning PCa from previous datasets of the Cancer Genome Atlas (TCGA) and the gene expression omnibus (GEO) was performed. Lasso and Cox regression analyses were performed to develop and validate a novel signature to help predict BCR risk. Moreover, a nomogram was constructed by combining the signature and clinical variables.

Results: A total of 977 patients were involved in the study. This consisted of patients from the TCGA (n=405), GSE21034 (n=131), GSE70770 (n=193) and GSE116918 (n=248) datasets. A 9-mRNA signature was identified in the TCGA dataset (composed of C9orf152, EPHX2, ASPM, MMP11, CENPF, KIF4A, COL1A1, ASPN, and FANCI) which was significantly associated with BCR (HR =3.72, 95% CI: 2.30–6.00, P<0.0001). This signature was validated in the GSE21034 (HR =7.54, 95% CI: 3.15–18.06, P=0.019), GSE70770 (HR =2.52, 95% CI: 1.50–4.22, P=0.0025) and GSE116918 datasets (HR =4.75, 95% CI: 2.51–9.02, P=0.0035). Multivariate Cox regression and stratified analysis showed that the 9-mRNA signature was a clinical factor independent of prostate-specific antigen (PSA), Gleason score (GS), or AJCC T staging. The mean AUC for 5-year BCR-free survival predictions of the 9-mRNA signature (0.81) was higher than the AUC for PSA, GS, or AJCC T staging (0.52–0.73). Furthermore, we combined the 9-mRNA signature with PSA, GS, or AJCC T staging and demonstrated that this could enhance prognostic accuracy.

Conclusions: The proposed 9-mRNA signature is a promising biomarker for predicting BCR-free survival in PCa. However, further controlled trials are needed to validate our results and explore a role in individualized management of PCa.

Keywords: Prostate cancer; biochemical recurrence; TCGA and GEO; prognostics signature; nomogram

Submitted Jun 20, 2020. Accepted for publication Sep 28, 2020.

doi: 10.21037/tau-20-1019

View this article at: <http://dx.doi.org/10.21037/tau-20-1019>

[^] ORCID: Xiangkun Wu, 0000-0002-4952-9170; Yongda Liu, 0000-0003-2032-1314.

Introduction

Prostate cancer (PCa) is the second most commonly diagnosed cancer and the fifth leading cause of cancer related deaths globally (1). There have been four previous studies which have reported that approximately 20–40% of patients experience a biochemical recurrence (BCR) after radical prostatectomy (RP) (2–4). According to the guidelines of the European Association of Urology and the American Urological Association, BCR is defined as two consecutive prostate-specific antigen (PSA) values of ≥ 0.2 ng/mL following RP (5,6). Although the BCR is not equivalent to clinical recurrence after RP (5), it is a decisive risk factor for PCa-specific mortality and overall mortality (7). In the absence of secondary therapy following BCR, around 30% of patients have a median period of 5–8 years before clinical progression and 32–45% among these patients would suffer PCa-specific mortality within 15 years (8). Therefore, it is crucial to identify these high-risk patients early and accurately in order to evaluate their prognosis and tailor patient-specific follow-up and management.

Clinicopathological parameters such as the Gleason score (GS), pathological tumor staging (pT), and PSA are associated with the survival of PCa patients and can predict the incidence of BCR. In 1998, D'Amico *et al.* (9) first proposed a risk classification method based on pT staging, GS, and PSA to predict the risk of BCR. Subsequently, the CAPRA nomogram by Cooperberg *et al.* (10), the nomogram by Stephenson *et al.* (11), a risk classification system by the National Comprehensive Cancer Network (12), and the Genomic Prostate Score (GPS) (13) are also based on clinical pathology variables. However, current risk stratification methods explain only a proportion of the observed variation in clinical outcomes and is not accurate enough to identify patients at high-risk of BCR (14–16). Molecular properties or biomarkers, such as alterations at both the genetic and protein levels, have been identified which allows the identification of risk-predictive signatures that can improve the clinical outcome (17–20). However, there is a critical requirement to improve the evaluation of BCR (21).

In this study, we aimed to: (I) identify mRNAs associated with BCR by Cox regression analysis of mRNA sequencing data obtained from the gene expression omnibus (GEO) and the Cancer Genome Atlas (TCGA) database; (II) construct and validate the mRNA signature and a nomogram combined signature with clinicopathological parameters

to identify patients with high-risk BCR; and (III) analyse biological signaling pathway of the mRNA signature by Gene Set Enrichment Analysis (GSEA). We present the following article in accordance with the TRIPOD reporting checklist (available at <http://dx.doi.org/10.21037/tau-20-1019>).

Methods

Data processing

In this study, three independent datasets with their gene expression profile matrix files and corresponding clinical data were downloaded from the GEO dataset (<https://www.ncbi.nlm.nih.gov/geo/>). These included the GSE21034, GSE70770, and GSE116918 datasets. The average expression value for mRNA was used if multiple probes matched a single mRNA. The mRNAs with average expression values < 1 were removed. The 'sva' package (Version: 3.36.0; <http://bioconductor.org/packages/release/bioc/html/sva.html>) was used to remove batch effects.

RNA-sequencing data and the corresponding clinical data of patients with PCa were downloaded from the TCGA (<https://portal.gdc.cancer.gov>). The count data (RNAseq) was transformed by variance stabilizing transformation using "DESeq2" package. The mRNAs with an average expression value < 1 were removed. A total of 977 patients with complete clinical information, including PSA, GS and pT staging were enrolled. This consisted of 405 patients from the TCGA dataset, 131 from the GSE21034 dataset, 193 from the GSE70770 dataset, and 248 from the GSE116918 dataset.

The TCGA and GEO datasets were extracted from a public database and required no ethical approval. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Construction and validation of the mRNA-based prognostic signature

In order to obtain a consistent formula and a uniform cutoff value to divide PCa patients into low- and high-risk groups, we normalized for the expression values of mRNAs in TCGA, GSE21034, GSE70770, and GSE116918 datasets with a standard deviation (SD) = 1 and mean value = 0. Univariate Cox regression analysis was used to analyze the association between gene expression and BCR in each cohort. P values of < 0.05 were considered statistically

significant. Common prognostic genes between the four datasets were selected and LASSO analysis was performed to pinpoint which mRNAs could be used for the prediction of BCR using the “glmnet” package. Finally, based on the results of the LASSO analysis, we performed multivariate Cox regression analyses to establish the mRNA signature from the TCGA dataset. The risk score for each patient was calculated by combining the expression values of prognostic genes and their regression coefficients. All patients were classified into either high-risk or low-risk groups based on their median risk score. The risk score of each patient in the GSE21034, GSE70770, and GSE116918 datasets were calculated using the same formula. Each dataset was divided into high and low-risk groups according to the same cutoff values. Kaplan-Meier analysis with log-rank test was used to assess the difference in BCR-free survival between the high-risk and low-risk groups. The time-dependent receiver operating characteristic (ROC) analysis with area under the curve (AUC) was used to evaluate the diagnostic performance of the signature. A concordance index (C-index) using 1000 bootstrap resamples was also used to assess the prognostic accuracy of the signature with clinical data. We used the “survcomp” package to compare the C-index between the 9-mRNA signature and D’Amico model (9) which was developed based on the clinical T stage, preoperative PSA, and GS.

Independence of the mRNA signature from clinical characteristics

Univariate and multivariable Cox regression analyses were performed to assess whether the risk score was independent of GS, pT staging, or PSA. To further identify whether the mRNA signature was a statistically significant prognostic factor in its own regard, the patients were stratified by clinical characteristics and a Kaplan-Meier survival analysis was used to assess the difference in BCR-free survival between high-risk and low-risk subgroups.

Construction of the nomogram

The nomogram was constructed by combining the mRNA-based prognostic signature and clinical variables from the TCGA dataset. Calibration plots and C-index were performed to assess the prognostic performance of the nomogram. The C-index was calculated using a bootstrap method with 1,000 resamples and displayed a degree of consistency between the actual observed outcome

probabilities and predicted probabilities. The x and y-axis of the calibration plot showed nomogram-predicted recurrence and observed outcome, respectively. The 45° line represented the best prediction.

Functional enrichment analysis and gene set enrichment analysis

GO and KEGG pathway enrichment analyses were conducted to identify the biological processes, cellular components, and molecular functions of the mRNAs related to BCR identified in the four datasets. Functions displaying significance were explored using the “clusterProfile” package. Gene set enrichment analysis (GSEA) was performed to identify significantly altered molecular mechanisms associated with the prognostic gene signature using the JavaGSEA software. A total of 405 PCa samples from the TCGA dataset were divided into high and low-risk groups according to the median risk score and annotated gene set `c2.cp.kegg.v7.0.symbols.gmt` was explored to identify enriched KEGG pathways associated with the poor prognosis of the high-risk group. FDR <0.05 and $|NES| >1$ were considered as the cut-off criteria.

Statistical analysis

All statistical analysis was conducted in R v. 3.6.1. Cox regression analysis was performed using the “survival” package to evaluate survival probability. The hazard ratio (HR) and 95% confidence interval (CI) were used to assess the association between signature and survival. Chi-square test or Fisher’s exact tests were used to examine the association between the patients with and without BCR and the clinical information. All P values <0.05 were considered statistically significant.

Results

Identification of commonly BCR-related mRNAs of four datasets

Candidate genes that were associated with BCR from each dataset were identified and the most credible prognostic genes of the four overlapping datasets were selected. The prognostic signature was then developed using the Cox proportional hazard regression model and the TCGA dataset, followed by validation using the GSE21034, GSE70770, and GSE116918 datasets. Finally, we developed




Figure 1 Study flow diagram. The blue, yellow, green and red circles refer to the TCGA, GSE21034, GSE70770 and GSE116918 datasets, respectively. HR, hazard ratio.

a nomogram based on the prognostic signature and clinicopathological parameters. These were again validated using the GSE21034, GSE70770, and GSE116918 datasets (Figure 1).

Clinical characteristics of the patients (PSA, GS, pT staging, and follow-up time) from the TCGA and GEO datasets are shown in Table 1 and Table S1. The median follow-up time for the TCGA, GSE21034, GSE70770, and GSE116918 cohorts were 31.5, 47.5, 54.1, and 78.3 months, respectively. The platforms for the GSE21034, GSE70770, and GSE116918 datasets were the Affymetrix Human Exon 1.0 ST Array, Illumina HumanHT-12 V4.0 expression beadchip, and Almac Diagnostics Prostate Disease Specific Array (Table S2).

In this study, a univariate Cox regression analysis was performed for each dataset and candidate prognostic mRNAs that were significantly associated with BCR were identified using the cutoff values of $P < 0.05$ and $|HR| > 1.0$. A total of 2,822 mRNAs in the TCGA dataset, 436 mRNAs in the GSE21034 dataset, 2,243 mRNAs in the

GSE70770 dataset, and 830 mRNAs in the GSE116918 dataset were identified as candidate risk factors. A total of 2,115 mRNAs in the TCGA dataset, 564 mRNAs in the GSE21034 dataset, 956 mRNAs in the GSE70770 dataset, and 647 mRNAs in the GSE116918 dataset were identified as candidate protective factors. Candidate prognostic mRNAs from the four datasets were intersected, and a total of 21 mRNAs associated with increased risk and 4 mRNAs associated with protection were identified.


Construction of the mRNA-based prognostic signature

To further analyse the mRNAs common to all the datasets which were associated with BCR, LASSO analysis was used to shrink all the regression coefficients towards zero and select variables simultaneously. The minimum criteria as the optimal lambda values were determined through 10-fold cross-validations (Figure 2). Finally, using multivariate Cox analysis, we identified a 9-mRNA signature that was significantly associated with BCR risk in PCa patients. The

Table 1 Clinicopathological characteristics of the TCGA cohort

Characteristics	All patients	Patients with biochemical recurrence	Patients without biochemical recurrence	P value
Patients, n (%)	405 (100.0)	67 (16.5)	338 (83.5)	
PSA, n (%)				<0.0001
<10 ng/mL	269 (66.4)	32 (47.8)	237 (70.1)	
≥10 ng/mL	136 (33.6)	35 (52.2)	100 (29.9)	
AJCC T staging, n (%)				<0.0001
pT2	148 (36.5)	5 (7.4)	143 (62.7)	
pT3T4	257 (63.5)	62 (92.6)	195 (57.3)	
Gleason score, n (%)				<0.0001
≤7	237 (58.5)	18 (26.9)	219 (64.8)	
≥8	171 (42.2)	49 (73.1)	119 (35.2)	
Race, n (%)				<0.0001
White	336 (83.0)	59 (88.1)	277 (82.0)	
Others	69 (17.0)	8 (11.9)	61 (18.0)	
Follow-up after surgery				<0.0001
Median months (range)	31.5 (1–167.5)	86.4 (1–167.5)	16.0 (1–77.0)	

TCGA, The Cancer Genome Atlas.

**Figure 2** The LASSO analysis via 10-fold cross-validation with minimum criteria. (A) Tuning parameter selection via 10-fold cross-validation with minimum criteria in the LASSO model. (B) LASSO coefficient profiles of 25 prognostic mRNAs. LASSO, least absolute shrinkage and selection operator.




Figure 3 Prognostic analysis of the 9-mRNA signature. Risk score (A), Kaplan-Meier plots (B) and time-dependent ROC curves (C) of the 9-mRNA signature for the TCGA dataset. TCGA, The Cancer Genome Atlas; BCR, biochemical recurrence; HR, hazard ratio; AUC, area under the curve; TPR, true positive rate; FPR, false positive rate; C9orf152, chromosome 9 open reading frame 152; EPHX2, epoxide hydrolase 2; ASPM, assembly factor for spindle microtubules; MMP11, matrix metalloproteinase 11; CENPF, centromere protein F; KIF4A, kinesin family member 4A; COL1A1, collagen type I alpha 1 chain; ASPN, Aspirin; FANCI, FA complementation group I.

univariate Cox regression analysis result for the 9-mRNAs is shown in Table S3. The mRNAs C9orf152 and EPHX2 with HR <1 were considered protective mRNAs, whereas the mRNAs ASPM, MMP11, CENPF, KIF4A, COL1A1, ASPN, and FANCI with HR >1 were regarded as risk-associated mRNAs. The risk score was calculated as follows: $[0.68 \times \text{Expression value of ASPM}] + [0.79 \times \text{Expression value of MMP11}] + [0.51 \times \text{Expression value of CENPF}] + [0.14 \times \text{Expression value of KIF4A}] + [1.17 \times \text{Expression value of COL1A1}] + [0.39 \times \text{Expression value of ASPN}] + [1.11 \times \text{Expression value of FANCI}] + [(-1.59) \times \text{Expression value of C9orf152}] + [(-1.29) \times \text{Expression value of EPHX2}]$.

The TCGA cohort was stratified into either a high-risk group or low-risk group based on the median risk score. The risk score distribution, mRNA expression, and BCR status of patients from the TCGA dataset are shown and ranked based on the risk score values of the 9-mRNA signature (Figure 3A).

The Kaplan-Meier survival curves showed that the patients with the higher risk scores had significantly higher risk of BCR compared to those in the low risk group (HR =3.72, 95% CI: 2.30–6.00, $P < 0.0001$; Figure 3B). The AUCs for 3- and 5-year BCR-free survival predictions for the 9-mRNA signature were 0.75 and 0.71, respectively (Figure 3C). This indicated that the 9-mRNA signature had high sensitivity and specificity as a diagnostic marker. The C-index of the 9-mRNA signature was 0.72 (95% CI:

0.66–0.78, $P < 0.0001$). The C-index for BCR-free survival predictions for the 9-mRNA signature was higher than D’Amico model (9) for the TCGA dataset, but it was not statistically significant (Table S4).

Additionally, multivariate Cox regression analysis showed that the 9-mRNA signature was an independent risk factor after adjusting for the clinicopathological variables (Table 2). The Kaplan-Meier survival curves showed that the 9-mRNA signature was still a statistically significant prognostic factor regardless of clinical data (Figure S1).

Validation of the 9-mRNA signature

To further evaluate the diagnostic potential of the 9-mRNA signature, we performed the same analysis as mentioned above for three external validation datasets, including GSE21034, GSE70770, and GSE116918. The risk scores for all the patients in the validation cohorts were calculated using the same formula and were divided into high and a low-risk groups based on the same cutoff. The risk score distribution, mRNA expression, and BCR status of patients for these external validation datasets can be found in Figure 4A,B,C. Significantly higher BCR-free survival rates were observed in the low-risk groups, compared with the high-risk groups for each validation dataset (HR >1, $P < 0.05$; Figure 4D,E,F).

ROC curve analysis also displayed good prognostic performance for patients in all the datasets (Figure 4G,H,I).




Figure 4 Validation of the 9-mRNA signature. Risk score, Kaplan-Meier plots and time-dependent ROC curves of the 9-mRNA signature for the GSE21034 dataset (A,D,G), GSE70770 (B,E,H), GSE116918 (C,F,I). BCR, biochemical recurrence; HR, hazard ratio; AUC, area under the curve; TPR, true positive rate; FPR, false positive rate; C9orf152, chromosome 9 open reading frame 152; EPHX2, epoxide hydrolase 2; ASPM, assembly factor for spindle microtubules; MMP11, matrix metalloproteinase 11; CENPF, centromere protein F; KIF4A, kinesin family member 4A; COL1A1, collagen type I alpha 1 chain; ASPN, Aspirin; FANCI, FA complementation group I.

Table 2 Cox regression analysis of the 9-mRNA signature and BCR of PCa in 4 independent datasets

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
TCGA				
Gleason score (≥ 8 vs. ≤ 7)	1.89 (1.53–2.35)	<0.0001*	1.70 (0.98–2.96)	0.058
AJCC T (T3&T4 vs. T2)	3.71 (2.09–6.61)	<0.0001*	2.02 (1.07–3.82)	0.029*
PSA (ng/mL) (≥ 10 vs. <10)	2.07 (1.28–3.34)	0.00030*	1.28(0.78–2.10)	0.33
Risk score (high vs. low)	7.65 (3.07–19.04)	<0.0001*	4.37 (1.67–11.46)	0.0026*
GSE21034				
Gleason score (≥ 8 vs. ≤ 7)	2.58 (1.93–3.45)	<0.0001*	2.27 (1.60–3.23)	<0.0001*
AJCC T (T3&T4 vs. T2)	3.74 (1.84–7.60)	0.00020*	1.60 (0.71–3.62)	0.25
PSA (ng/mL) (≥ 10 vs. <10)	3.0 (1.48–6.0)	0.0020*	1.04 (0.48–2.26)	0.91
Risk score (high vs. low)	1.33 (1.20–1.46)	<0.0001*	1.31(1.13–1.52)	0.00035*
GSE70770				
Gleason score (≥ 8 vs. ≤ 7)	1.21 (0.99–1.48)	0.058	1.03 (0.81–1.31)	0.76
AJCC T (T3&T4 vs. T2)	0.99 (0.58–1.71)	0.99	1.25 (0.65–2.40)	0.49
PSA (ng/mL) (≥ 10 vs. <10)	1.85 (1.01–3.40)	0.048*	1.25 (0.72–2.17)	0.43
Risk score (high vs. low)	1.41 (1.25–1.58)	<0.0001*	1.40 (1.23–1.58)	<0.0001*
GSE116918				
Gleason score (≥ 8 vs. ≤ 7)	1.26 (0.98–1.62)	0.071	0.86 (0.64–1.16)	0.33
AJCC T (T3&T4 vs. T2)	2.02 (1.19–3.43)	0.0088*	1.65 (0.92–2.97)	0.094
PSA (ng/mL) (≥ 10 vs. <10)	1.64 (0.78–3.47)	0.20	1.21 (0.56–2.61)	0.63
Risk score (high vs. low)	1.47 (1.27–1.69)	<0.0001*	1.48 (1.26–1.74)	<0.0001*

PCa, prostate cancer; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; TCGA, The Cancer Genome Atlas. *P<0.05.

The C-index of the GSE21034, GSE70770, and GSE116918 datasets were 0.79 (95% CI: 0.71–0.87, P<0.0001), 0.74 (95% CI: 0.67–0.80, P<0.0001), 0.71 (95% CI: 0.64–0.78, P<0.0001), respectively. Furthermore, we compared the C-index between the 9-mRNA signature and D'Amico model (Table S4). Although not statistically significant, the C-index for the BCR-free survival predictions for the 9-mRNA signature was higher than the D'Amico model (9) for the GSE70770 and GSE116918 datasets. The univariate and multivariate Cox regression analysis also indicated that the 9-mRNA signature was an independent risk factor (Table 2).

Construction of the nomogram

To quantitatively predict the probability of BCR during PCa,

we created a nomogram by combining the mRNA-based prognostic signature and clinical variables and applied it to the TCGA dataset to predict 3- and 5-year BCR probability (Figure 5). The mRNA signature-based nomogram performed well and could predict the BCR for the TCGA dataset (C-index =0.74, 95% CI: 0.68–0.80, P<0.0001), GSE21034 dataset (C-index =0.85, 95% CI: 0.78–0.91, P<0.0001), GSE70770 dataset (C-index =0.76, 95% CI: 0.70–0.83, P<0.0001), and GSE116918 dataset (C-index =0.71, 95% CI: 0.64–0.79, P<0.0001). The C-index for BCR-free survival predictions for the nomogram was higher than D'Amico model for the TCGA, GSE21034, GSE70770 and GSE116918 datasets (Table S5). The calibration plots also demonstrated that the nomogram performed highly and was an ideal model both for the TCGA cohort and validation cohorts (Figure 6).




Figure 5 Nomogram to predict risk of BCR. The nomogram constructed by risk score, Gleason score and AJCC T staging. BCR, biochemical recurrence.

Validation of the expression of the 9 mRNAs

The expression values of the 9 mRNAs were validated using the UALCAN website (<http://ualcan.path.uab.edu/>). The mRNA expression values for ASPM, ASPN, C9orf152, CENPF, COL1A1, FANCI, KIF4A, and MMP11 were significantly increased in PCa tissue compared with normal tissues. In contrast, EPHX2 expression was significantly decreased (Figure 7). We also used the Human protein atlas website (<https://www.proteinatlas.org/>) to explore protein expression of the 8 mRNAs. Typical immunohistochemistry of the 8 mRNAs (except ASPM, not recorded in the website) in tumor and normal prostate tissues are shown in Figure 8.

Functional enrichment analysis and gene set enrichment analysis

The mRNAs from the four datasets were significantly involved in nuclear division, organelle fission, and mitotic nuclear division (Figure 9A). We also performed GSEA analysis on the high- and low-risk groups from the TCGA dataset to identify biological pathways significantly associated with the 9-mRNA signature. Based on the cut-off criteria of FDR <0.05, three KEGG pathways were significantly enriched in the high-risk group. These included the cell cycle pathway, DNA replication pathway, and mismatch repair pathway (Figure 9B). These significantly altered pathways in the high-risk group were closely related to the malignant properties of PCa, and

especially related to the BCR of PCa.

Discussion

Approximately 30% of PCa patients after RP would experience BCR. These patients only have a median period of between 5-8 years prior to clinical progression and require immediate intervention. Early prediction of BCR is therefore important to reduce the mortality of PCa, and a new predictive method to stratify PCa patients into those at high or low risk of BCR has significant clinical applications.

Our enhanced understanding of genetic changes during PCa has facilitated the identification of predictive and prognostic signatures; allowing personalized diagnoses and treatment management. Numerous studies have reported various genetic signatures; including mRNA, miRNA, and lncRNA signatures that could predict BCR (22-24). However, these signatures have different predictive potential, have not been well verified, and their clinical applications are poorly understood. At present, much of the sequencing data for PCa has been uploaded to the publicly available TCGA and GEO databases, which has allowed a comprehensive bioinformatic analyse to discover and validate novel prognostic signatures for PCa.

In this retrospective study, a 9-mRNA prognostic signature was identified which could predict the BCR of PCa in the TCGA dataset. Patients at high risk of BCR had a significantly poorer prognosis than those at low risk. Moreover, C-index and ROC analysis identified that the 9-mRNA signature was excellent




Figure 6 The 3- and 5-yr nomogram calibration curves. (A) TCGA dataset. (B) GSE21034 dataset. (C) GSE70770 dataset. (D) GSE116918 dataset. TCGA, The Cancer Genome Atlas.

for predicting the 3-, 5- and 10-year BCR events. Furthermore, the 9-mRNA signature was shown to be a strong prognostic and independent risk factor after adjusting for clinicopathological variables, including the GS, T staging, and PSA. We further validated the 9-mRNA signature in three external datasets (GSE21034, GSE70770, GSE116918) and found similar results. These results demonstrated that the 9-mRNA signature could effectively stratify patients into high- and low-risk groups, predict BCR-free survival probability, and was an effective prognostic factor for PCa. Subsequently, a nomogram

combining the 9-mRNA signature and clinicopathologic features was created and validated in our study with the aim of aiding clinical decision-making for physicians. Notably, calibration plots demonstrated that the nomogram was effective for predicting the BCR in the discovery and validation sets.

Our 9-mRNA signature displayed better diagnostic potential with a 5-year AUC of 0.71 in the TCGA cohort, 0.81 in the GSE21034 cohort, 0.92 in the GSE70770 cohort, and 0.78 in the GSE116918 cohort. The mRNA-based nomogram could be used to stimulate new methods




Figure 7 Expression pattern of ASPM (A), ASPN (B), C9orf152 (C), CENPF (D), COL1A1 (E), EPHX2 (F), FANCI (G), KIF4A (H) and MMP11 (I) between prostate cancer and adjacent normal tissue. PRAD, prostate cancer; C9orf152, chromosome 9 open reading frame 152; EPHX2, epoxide hydrolase 2; ASPM, assembly factor for spindle microtubules; MMP11, matrix metalloproteinase 11; CENPF, centromere protein F; KIF4A, kinesin family member 4A; COL1A1, collagen type I alpha 1 chain; ASPN, Aspirin; FANCI, FA complementation group I.

and ideas based on adjuvant therapies for future clinical research and stratify high- and low-risk BCR patients. Moreover, the C-index of the mRNA-based nomogram was higher than D'Amico model (9) in the TCGA and validation datasets. However, the 9-mRNA signature needs further clinical validation and we will conduct a long-term follow-up of PCa patients to verify our nomogram in the future.

In the 9-mRNA signature, EPHX2 mRNA has been associated with AR in primary PCa. Here, its inhibition could decrease AR signaling *in vitro* and enhance the effects of antiandrogenic flutamide in PCa cells (25). The

presence of EPHX2 in the signature made us confident that the mRNA signature was reliable. Pai *et al.* (26) found that ASPM mRNA (a potential regulator of Wnt signaling) was significantly up-regulated in primary and metastatic PCa and was positively correlated with low BCR-free survival probability. MMP11 mRNA is associated with poor prognosis for PCa (27) and MMP11 expression in advanced PCa is significantly higher than in localized PCa (28). Aytes *et al.* discovered that co-expression of CENPF and FOXM1 is a signature for poor prognosis in PCa. Moreover, CENPF and FOXM1 act as synergistic master regulators to promote tumor growth and PCa malignancy (29).




Figure 8 The representative protein expression of the 8 mRNAs (except ASPM) in prostate cancer and normal tissue. C9orf152, chromosome 9 open reading frame 152; EPHX2, epoxide hydrolase 2; ASPM, assembly factor for spindle microtubules; MMP11, matrix metalloproteinase 11; CENPF, centromere protein F; KIF4A, kinesin family member 4A; COL1A1, collagen type I alpha 1 chain; ASPN, Aspirin; FANCI, FA complementation group I.

ASPN as a critical mesenchymal stromal cell factor is extensively affected by the PCa microenvironment and is correlated with PCa, BCR, and metastasis (30,31). The studies above highlighted that the inclusion of EPHX2, ASPM, MMP11, CENPF, and ASPN in the 9-mRNA signature was warranted. However, the roles of the remaining

four mRNAs (C9orf152, KIF4A, COL1A1 and FANCI) in PCa are unknown. Additionally, these four mRNAs may have potential for molecular targeted therapy, as this study showed their association with biological pathways involved in PCa. Future studies will therefore focus on these four mRNAs and investigate their roles in PCa.




Figure 9 (A) Functional Enrichment the commonly prognosis mRNAs of four datasets. (B) Gene set enrichment analysis in TCGA dataset. KEGG, Kyoto Encyclopedia of Genes and Genomes.

Conclusions

Here, we identified and validated a 9-mRNA signature which could predict the BCR of PCa, precisely stratify patients into those at high or low risk of BCR, and augment the ability of clinicians to decide on personalized therapies. However, further controlled trials are needed to validate our results and to test their clinical applications for individualized management of PCa.

Acknowledgments

Funding: This study was supported by grants from National Natural Science Foundation of China (No. 81600542 and 81670643); the Natural Science Foundation of Guangdong Province (2020A1515010464), the Guangdong Basic and Applied Basic Research Foundation (Grant NO. 2019A1515110033); Distinguished Young Talents in Higher Education Foundation of Guangdong Province (Grant NO. 2019KQNCX115 and 2020KZDZX1168); China Postdoctoral Science Foundation (Grant NO. 2019M662865); Achievement cultivation and clinical transformation application cultivation projects of the First Affiliated Hospital of Guangzhou Medical University (Grant NO. ZH201908).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <http://dx.doi.org/10.21037/tau-20-1019>

Peer Review File: Available at <http://dx.doi.org/10.21037/tau-20-1019>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tau-20-1019>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The TCGA and GEO datasets were extracted from a public database and required no ethical approval.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons

Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30.
2. Liesenfeld L, Kron M, Gschwend JE, et al. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. *J Urol* 2017;197:143-8.
3. Ludwig WW, Feng Z, Trock BJ, et al. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years? *J Urol* 2018;199:114-9.
4. Pak S, You D, Jeong IG, et al. Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer. *Int J Clin Oncol* 2019;24:1238-46.
5. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. *J Urol* 2007;177:540-5.
6. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. *Eur Urol* 2017;71:630-42.
7. Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. *Eur Urol* 2019;75:967-87.
8. Brockman JA, Alanee S, Vickers AJ, et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol* 2015;67:1160-7.
9. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998;280:969-74.
10. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. *J Urol* 2005;173:1938-42.
11. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Clin Oncol* 2005;23:7005-12.
12. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. *J Natl Compr Canc Netw* 2010;8:145.
13. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics* 2013;14:690.
14. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature. *Clin Cancer Res* 2008;14:4400-7.
15. Lorent M, Maalmi H, Tessier P, et al. Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA). *BMC Med Inform Decis Mak* 2019;19:2.
16. Remmers S, Verbeek JFM, Nieboer D, et al. Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer. *BJU Int* 2019;124:635-42.
17. Amaro A, Esposito AI, Gallina A, et al. Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. *Cancer Metastasis Rev* 2014;33:657-71.
18. Hiser WM, Sangiorgio V, Bollito E, et al. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. *Future Oncol* 2018;14:3073-83.
19. Spratt DE, Zhang J, Santiago-Jiménez M, et al. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. *J Clin Oncol* 2018;36:581-90.
20. Fine ND, LaPolla F, Epstein M, et al. Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer. *BJU Int* 2019. [Epub ahead of print].
21. Lin X, Kapoor A, Gu Y, et al. Assessment of biochemical recurrence of prostate cancer (Review). *Int J Oncol* 2019;55:1194-212.
22. Penney KL, Sinnott JA, Fall K, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer.

- J Clin Oncol 2011;29:2391-6.
23. Shao N, Tang H, Qu Y, et al. Development and validation of lncRNAs-based nomogram for prediction of biochemical recurrence in prostate cancer by bioinformatics analysis. *J Cancer* 2019;10:2927-34.
 24. Zhao Z, Weickmann S, Jung M, et al. A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. *Cancers (Basel)* 2019;11:1603.
 25. Vainio P, Gupta S, Ketola K, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. *Am J Pathol* 2011;178:525-36.
 26. Pai VC, Hsu CC, Chan TS, et al. ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3- β -catenin signaling. *Oncogene* 2019;38:1340-53.
 27. Roscilli G, Cappelletti M, De Vitis C, et al. Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. *J Transl Med* 2014;12:54.
 28. Fernandez-Gomez JM, Eiro N, García-Rodríguez JJ, et al. Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts. *Actas Urol Esp*;41:376-82.
 29. Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. *Cancer Cell* 2014;25:638-51.
 30. Rochette A, Boufaied N, Scarlata E, et al. Asporin is a stromally expressed marker associated with prostate cancer progression. *Br J Cancer* 2017;116:775-84.
 31. Hughes RM, Simons BW, Khan H, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. *Cancer Res* 2019;79:3636-50.

Cite this article as: Wu X, Lv D, Eftekhari M, Khan A, Cai C, Zhao Z, Gu D, Liu Y. A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients. *Transl Androl Urol* 2020;9(6):2572-2586. doi: 10.21037/tau-20-1019

Table S1 Clinical characteristics of the patients in GSE21034, GSE70770 and GSE116918 datasets

Characteristics	All patients	Patients with biochemical recurrence	Patients without biochemical recurrence	P value
Clinicopathological characteristics of the GSE21034				
Patients, n (%)	131 (100.0)	32 (24.4)	99 (75.6)	
PSA, n (%)				<0.0001
<10 ng/mL	100 (66.4)	15 (48.9)	83 (83.8)	
≥10 ng/mL	31 (33.6)	17 (51.1)	16 (16.2)	
AJCC T staging, n (%)				0.001
T2	85 (36.5)	13 (40.6)	72 (72.7)	
T3T4	46 (63.5)	19 (59.4)	27 (27.3)	
Gleason score, n (%)				<0.0001
≤7	106 (80.9)	20 (62.5)	96 (97.0)	
≥8	15 (19.1)	12 (37.5)	3 (3.0)	
Follow-up after surgery				
Median months (range)	47.5 (1.4–147.1)	30.5 (1.4–91.9)	53.0 (1.8–147.1)	<0.0001
Clinicopathological characteristics of the GSE70770				
Patients, n (%)	193 (100)	59 (30.1)	134 (69.4)	
PSA, n (%)				0.26
<10 ng/mL	132 (68.4)	37 (62.7)	95 (70.9)	
≥10 ng/mL	61 (31.6)	22 (27.3)	39 (29.1)	
AJCC T staging, n (%)				0.001
T2	78 (40.4)	15 (25.4)	71 (53.0)	
T3T4	115 (59.6)	44 (74.6)	63 (47.0)	
Gleason score, n (%)				<0.0001
≤7	173 (89.6)	46 (78.0)	127 (94.8)	
≥8	20 (10.4)	13 (22.0)	7 (5.2)	
Follow-up after surgery				
Median months (range)	54.1 (1.8–115.5)	67.6 (2.0–115.5)	48.2 (1.8–103.4)	<0.0001
Clinicopathological characteristics of the GSE116918				
Patients, n (%)	248 (100)	56 (22.6)	192 (77.4)	
PSA, n (%)				0.213
<10 ng/mL	50 (20.2)	8 (14.3)	42 (21.9)	
≥10 ng/mL	198 (79.8)	48 (85.7)	150 (78.1)	
AJCC T staging, n (%)				0.005
T2	152 (61.3)	25 (44.6)	127 (66.1)	
T3T4	96 (38.7)	31 (55.4)	65 (38.9)	
Gleason score, n (%)				<0.0001
≤7	141 (56.9)	28 (50.0)	113 (58.9)	
≥8	107 (43.1)	28 (50.0)	79 (41.1)	
Follow-up after radical radiation therapy				
Median months (range)	78.3 (10.0–117)	58.8 (10.0–106.0)	83.9 (11.0–117)	<0.0001

PSA, prostate-specific antigen.

Table S2 Details of the GEO datasets included in this study

Dataset ID	Prostate cancer sample size	Platform
GSE21034	131	[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [probe set (exon) version]
GSE70770	193	Illumina HumanHT-12 V4.0 expression beadchip
GSE116918	248	[ADXPCv1a520642] Almac Diagnostics Prostate Disease Specific Array (DSA)

GEO, the gene expression omnibus.

Table S3 Univariate Cox regression analysis of 9 mRNAs and BCR-free survival of PCa patients in four datasets

Genes	TCGA		GSE21034		GSE70770		GSE116918	
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
ASPM	1.50 (1.22–1.84)	<0.0001	6.18 (2.11–18.14)	<0.0001	5.03 (2.60–9.74)	<0.0001	2.50 (1.51–4.12)	<0.0001
MMP11	1.43 (1.24–1.67)	<0.0001	3.31 (1.13–9.70)	0.02	1.48 (1.11–1.96)	0.007	4.10 (2.04–8.27)	<0.0001
CENPF	1.47 (1.23–1.75)	<0.0001	4.82 (2.28–10.21)	<0.0001	4.61 (2.50–8.49)	<0.0001	1.82 (1.89–2.79)	0.005
KIF4A	1.65 (1.35–2.00)	<0.0001	5.79 (1.68–20.00)	0.005	5.54 (2.50–12.30)	<0.0001	1.50 (1.06–2.11)	0.02
COL1A1	1.44 (1.20–1.72)	<0.0001	2.55 (1.57–4.12)	<0.0001	1.31 (1.04–1.67)	0.02	3.39 (1.84–6.26)	<0.0001
ASPN	1.44 (1.19–1.74)	<0.0001	2.91 (1.92–4.40)	<0.0001	6.211.05–36.76)	0.04	1.63 (1.24–2.14)	<0.0001
FANCI	1.78 (1.30–2.52)	0.001	3.77 (1.29–10.99)	0.01	9.90 (2.82–34.78)	0.0003	2.68 (1.07–6.74)	0.03
C9orf152	0.57 (0.44–0.75)	<0.0001	0.49 (0.30–0.80)	0.004	0.38 (0.24–0.60)	<0.0001	0.72 (0.53–1.00)	0.04
EPHX2	0.56 (0.43–0.72)	<0.0001	0.39 (0.23–0.66)	<0.0001	0.47 (0.30–0.75)	<0.0001	0.47 (0.25–0.87)	0.01

HR, hazard ratio; CI, confidence interval; C9orf152, chromosome 9 open reading frame 152; EPHX2, epoxide hydrolase 2; ASPM, assembly factor for spindle microtubules; MMP11, matrix metalloproteinase 11; CENPF, centromere protein F; KIF4A, kinesin family member 4A; COL1A1, collagen type I alpha 1 chain; ASPN, Aspirin; FANCI, FA complementation group I.

Table S4 Comparison of C-index between the 9-mRNA signature and D'Amico model

Dataset ID	D'Amico model (Reference models)	9-mRNA signature	P value
	C-index (95% CI)	C-index (95% CI)	
TCGA	0.71 (0.65–0.78)	0.72 (0.66–0.78)	0.68
GSE21034	0.84 (0.76–0.91)	0.79 (0.71–0.87)	0.86
GSE70770	0.72 (0.64–0.80)	0.74 (0.67–0.80)	0.32
GSE116918	0.64 (0.56–0.73)	0.71 (0.64–0.78)	0.066

C-index, concordance index; TCGA, The Cancer Genome Atlas.

Table S5 Comparison of C-index between the nomogram and D'Amico model

Dataset ID	D'Amico model (Reference models), C-index (95% CI)	Nomogram, C-index (95% CI)	P value
TCGA	0.71 (0.65–0.78)	0.74 (0.68–0.80)	0.68
GSE21034	0.84 (0.76–0.91)	0.85 (0.78–0.91)	0.20
GSE70770	0.72 (0.64–0.80)	0.76 (0.70–0.83)	0.055
GSE116918	0.64 (0.56–0.73)	0.71 (0.64–0.79)	0.026

C-index, concordance index; TCGA, The Cancer Genome Atlas.




Figure S1 Kaplan-Meier survival analysis for PCa patients according to the 9-mRNA signature stratified by clinicopathological variables in TCGA dataset. (A, B) Gleason score (GS); (C, D) PSA; (E, F) AJCC T staging. BCR, biochemical recurrence; PSA, prostate-specific antigen; GS, Gleason score; TCGA, The Cancer Genome Atlas.